Biomarin Pharmaceutical (BMRN) Selling, General & Administrative (2009 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 582.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 662.10 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -417.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 216.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 110.21 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 593.21 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 161.89 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 247.47 Mn |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | 395.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 395.55 Mn |
| Mar 31, 2026 | 258.29 Mn |
| Dec 31, 2025 | 446.21 Mn |
| Sep 30, 2025 | 268.42 Mn |
| Jun 30, 2025 | 232.28 Mn |
| Mar 31, 2025 | 206.12 Mn |
| Dec 31, 2024 | 266.61 Mn |
| Sep 30, 2024 | 253.48 Mn |
| Jun 30, 2024 | 263.03 Mn |
| Mar 31, 2024 | 225.91 Mn |
| Dec 31, 2023 | 259.51 Mn |
| Sep 30, 2023 | 215.77 Mn |
| Jun 30, 2023 | 206.10 Mn |
| Mar 31, 2023 | 211.02 Mn |
| Dec 31, 2022 | 214.97 Mn |
| Sep 30, 2022 | 216.82 Mn |
| Jun 30, 2022 | 196.84 Mn |
| Mar 31, 2022 | 194.62 Mn |
| Dec 31, 2021 | 217.56 Mn |
| Sep 30, 2021 | 183.33 Mn |